Resumen de las cotizaciones máximas, mínimas y variaciones del Bayer
Precios históricos de las acciones
Precio actual de la acción	€48.17
Máximo en las últimas 52 semanas	€53.92
Mínimo de 52 semanas	€25.78
Beta	0.83
Cambio en 1 mes	0.80%
Variación en 3 meses	32.66%
Cambio de 1 año	71.61%
Variación en 3 años	-2.49%
Variación en 5 años	6.55%
Variación desde la OPV	253.69%

Noticias y actualizaciones recientes

Actualización de narrativa • Sep 07

BAYN: Glyphosate Settlement Clarity Will Drive Future Re Rating Potential

Analysts report that the updated Bayer fair value estimate has shifted to €70.00 from €63.81, reflecting recent increases in price targets around €60 and expectations that glyphosate related legal risks may be more contained within existing provisions. Analyst Commentary Recent research updates on Bayer show a mix of views, although several bullish analysts highlight improving sentiment around legal risk and valuation.

Recent updates

Actualización de narrativa • Sep 07

BAYN: Glyphosate Settlement Clarity Will Drive Future Re Rating Potential

Actualización de narrativa • Aug 19

BAYN: Glyphosate Litigation Resolutions Will Drive Future Rerating Potential

Analysts have lifted their Bayer price expectations, with the updated fair value estimate moving from about €54.92 to roughly €56.83. This reflects higher Street price targets around €60 to €61 and increased confidence in the company's ability to contain glyphosate liabilities within existing provisions.

Actualización de narrativa • Aug 05

BAYN: Glyphosate Ruling And Mixed Pipeline Outlook Will Shape Future Re Rating Potential

Analysts have lifted their Bayer fair value estimate from €31.26 to €46.00, reflecting higher price targets in recent research and greater confidence that glyphosate liabilities could remain capped within existing provisions following the recent Supreme Court ruling. Analyst Commentary Recent research on Bayer has become more constructive after the Supreme Court ruling on glyphosate, but not all commentary is positive.

Actualización de narrativa • Jul 22

BAYN: Glyphosate Litigation Clarity Will Drive Future Rerating Potential

Analysts have lifted their Bayer fair value estimate from €34.97 to €54.92. This reflects updated assumptions on revenue growth, profit margins, and future P/E multiples following recent research that highlights reduced glyphosate liability uncertainty and mixed, but generally more constructive, rating and price target revisions across the Street.

Actualización de narrativa • Jul 08

BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating

The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.

Actualización de narrativa • Jun 24

BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating

Analysts nudged their average price target for Bayer slightly higher to about €40.50, citing updated views on litigation risks, the outlook for the asundexian pipeline, and recent recalibrations of valuation multiples such as forward P/E. Analyst Commentary Recent Street research around Bayer highlights a mixed but gradually improving tone, with several bullish analysts adjusting price targets and ratings as they reassess litigation exposure, the asundexian opportunity, and the conglomerate discount.

Artículo de análisis • Jun 16

Bayer (XTRA:BAYN) Stock Could Be 9.2% Undervalued After FDA Approval Of AMBELVIST

Bayer (XTRA:BAYN) is back in focus after the U.S. FDA approved AMBELVIST, a macrocyclic gadolinium based contrast agent for contrast enhanced MRI in adults and pediatric patients, including term neonates. See our latest analysis for Bayer. Despite recent product and leadership announcements, Bayer’s 1 year total shareholder return of 32.05% contrasts with a 5 year total shareholder return that is down 24.26%, while its 90 day share price return is down 9.7%. This suggests longer term holders...

Actualización de narrativa • Jun 06

BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating

Narrative Update on Bayer Analysts have lifted Bayer's blended price target to €40, with many highlighting higher published targets from firms such as DZ Bank, Deutsche Bank, Jefferies and UBS. They are still pointing to litigation outcomes and the asundexian data readout as key swing factors.

Actualización de narrativa • May 22

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.

Actualización de narrativa • May 05

BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential

Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.

Actualización de narrativa • Apr 21

BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential

Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.

Actualización de narrativa • Apr 06

BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside

Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.

Actualización de narrativa • Mar 23

BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings

Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.

Actualización de narrativa • Mar 09

BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings

Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.

Actualización de narrativa • Feb 23

BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside

The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.

Actualización de narrativa • Feb 09

BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside

Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.

Artículo de análisis • Jan 27

The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More

Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...

Actualización de narrativa • Jan 25

BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside

Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.

Actualización de narrativa • Jan 09

BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares

Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.

Actualización de narrativa • Dec 26

BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential

Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.

Actualización de narrativa • Dec 11

BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares

Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.

Artículo de análisis • Dec 03

Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce

Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...

Actualización de narrativa • Nov 27

BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares

Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.

Artículo de análisis • Nov 14

Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...

Actualización de narrativa • Nov 13

BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum

Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.

Rentabilidad de los accionistas

	BAYN	DE Pharmaceuticals	Mercado DE
7D	-1.4%	-2.4%	-1.8%
1Y	71.6%	39.7%	4.2%

Rentabilidad vs. Industria: BAYN superó a la industria German Pharmaceuticals, que obtuvo un rendimiento del 39.7% el año pasado.

Rentabilidad vs. Mercado: BAYN superó al mercado German, que obtuvo un rendimiento del 4.2% el año pasado.

Volatilidad de los precios

Is BAYN's price volatile compared to industry and market?
BAYN volatility
BAYN Average Weekly Movement	6.8%
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.2%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: BAYN no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BAYN (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1863	87,830	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft opera como empresa de ciencias de la vida en todo el mundo. La empresa opera a través de los segmentos Farmacéutico, Salud del Consumidor y Ciencias de los Cultivos. El segmento Farmacéutico suministra productos de prescripción principalmente para cardiología y salud de la mujer; especialidades terapéuticas en las áreas de oncología, hematología y oftalmología; y equipos de diagnóstico por imagen y agentes de contraste, así como terapia celular y génica.

Resumen de fundamentos de Bayer Aktiengesellschaft

¿Cómo se comparan los beneficios e ingresos de Bayer con su capitalización de mercado?
Estadísticas fundamentales de BAYN
Capitalización bursátil	€47.32b
Beneficios(TTM)	-€1.74b
Ingresos (TTM)	€45.38b

1.0x

Ratio precio-ventas (PS)

-27.2x

Ratio precio-beneficio (PE)

¿Está BAYN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BAYN
Ingresos	€45.38b
Coste de los ingresos	€17.94b
Beneficio bruto	€27.43b
Otros gastos	€29.17b
Beneficios	-€1.74b

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Nov 03, 2026

Beneficios por acción (BPA)	-1.77
Margen bruto	60.46%
Margen de beneficio neto	-3.83%
Ratio deuda/patrimonio	124.8%

¿Cómo se ha desempeñado BAYN a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

0.2%

Rentabilidad actual por dividendo

-6%

Ratio de pagos

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/13 20:09
Precio de las acciones al final del día	2026/09/11 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Bayer Aktiengesellschaft está cubierta por 40 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Rafael Bonardell Trianes	Banco de Sabadell. S.A.
Mark Purcell	Barclays
Charles Pitman	Barclays

Bayer (BAYN) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

Sustainable Farming And Rising Healthcare Will Fuel Expansion

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

Top Community Narratives

Bayer to Achieve Fair Value of €40 Boosting Growth and Investor Confidence

Top Community Narratives

Bayer to Achieve Fair Value of €40 Boosting Growth and Investor Confidence

Top Analyst Narratives

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

Sustainable Farming And Rising Healthcare Will Fuel Expansion

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

Competidores de Bayer Aktiengesellschaft

Merck KGaA

Dermapharm Holding

PEPTONIC medical

Sartorius

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Bayer Awaits Court Ruling on $7.25 Billion Roundup Settlement Proposal

FDA Grants Accelerated Approval to Bayer’s HYRNUO for HER2-Mutated Lung Cancer Treatment

Bayer Group Receives U.S. FDA Accelerated Approval For Sevabertinib As First-Line Treatment Option For Adults With HER2-Mutant Non-Small Cell Lung Cancer

Bayer Initiates Phase II Study of Investigational Girk4 Inhibitor in Patients with Atrial Fibrillation

BAYN: Glyphosate Settlement Clarity Will Drive Future Re Rating Potential

Bayer Begins Global Launches of New Crop Protection and Seed Blockbusters

Recent updates

Bayer Awaits Court Ruling on $7.25 Billion Roundup Settlement Proposal

FDA Grants Accelerated Approval to Bayer’s HYRNUO for HER2-Mutated Lung Cancer Treatment

Bayer Group Receives U.S. FDA Accelerated Approval For Sevabertinib As First-Line Treatment Option For Adults With HER2-Mutant Non-Small Cell Lung Cancer

Bayer Initiates Phase II Study of Investigational Girk4 Inhibitor in Patients with Atrial Fibrillation

BAYN: Glyphosate Settlement Clarity Will Drive Future Re Rating Potential

Bayer Begins Global Launches of New Crop Protection and Seed Blockbusters

Bayer Presents Phase III Reveal Study Results For Investigational Pet Radiotracer Iodine 124 Evuzamitide

Bayer Reports Positive Phase III Results for Cardiac Amyloidosis PET Radiotracer Study

Bayer Group Receives Approval For Sevabertinib In Japan For HER2-Mutant Non-Small Cell Lung Cancer

BAYN: Glyphosate Litigation Resolutions Will Drive Future Rerating Potential

Bayer Secures Canadian Approval for LYNKUET as First Therapy for Cancer-Related Hot Flashes

BAYN: Glyphosate Ruling And Mixed Pipeline Outlook Will Shape Future Re Rating Potential

One A Day Introduces New Women's Multi Gummy Formula With 1,000 Mcg Biotin

Bayer Partners With Kairos Pharma to Test New Prostate Cancer Combination Therapy

BAYN: Glyphosate Litigation Clarity Will Drive Future Rerating Potential

Bayer Retains Control as Apollo Takes €3 Billion Minority Stake in Contraceptives Business

BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating

Bayer Teams With University of Colorado to Accelerate Clinical Trial Research Across Key Diseases

Bayer Group to Consolidate U.S. Glyphosate Business into Distinct Entity Operating as Ruveon

Bayer Restructures U.S. Glyphosate Unit Into Ruveon LLC for Focused Market Operations

BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating

Bayer Teams With Iambic for AI-Powered Drug Discovery Targeting Challenging Diseases

Bayer Appoints Kacy Perry as Country Division Head for Crop Science Canada, Effective July 1, 2026

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Perfuse Therapeutics, Inc from Hatteras Venture Partners V, LP managed by Hatteras Venture Advisors VI, LLC, OrbiMed Advisors LLC and Access Industries (uk) Ltd.

Bayer (XTRA:BAYN) Stock Could Be 9.2% Undervalued After FDA Approval Of AMBELVIST

Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity

Bayer Awaits Key Decisions as EMA Reviews Asundexian for Stroke Prevention

Bayer Appoints Jost Reinhard as President of Radiology Business Within Bayer's Pharmaceuticals Division, Effective August 1, 2026

Bayer AG Announces Executive Changes

BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating

Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease

Bayer Seeks Legal Clarity on $7.25 Billion Roundup Settlement as Cash Flow Pressures Mount

Bayer Presents First Full FIND-CKD Results Investigating KERENDIA in Non-Diabetic Chronic Kidney Disease and Infinity Pooled Analysis At ERA 2026

Bayer Presents New Data Across Oncology Portfolio

Bayer Announces Priority Review Of Supplemental New Drug Application For Kerendia For Treatment Of Adults With Type 1 Diabetes And Chronic Kidney Disease

BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

Bayer Receives U.S. FDA Priority Review For Hyrnuo As First-Line Treatment Of Her2-Mutated Non-Small Cell Lung Cancer

First quarter 2026 earnings released: EPS: €2.81 (vs €1.32 in 1Q 2025)

Bayer Announces Positive Topline Results from the Phase III REVEAL Study

Bayer Aktiengesellschaft (XTRA:BAYN) entered into an agreement to acquire Perfuse Therapeutics, Inc. for $2.5 billion.

BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential

BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential

Upcoming dividend of €0.11 per share

BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside

Bayer AG Announces Appointment of Nelson Ambrogio as President of U.S. Pharmaceuticals, Effective May 1, 2026

BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings

Bayer Announces Kerendia Meets Primary Endpoint In Investigational Phase III Find-Ckd Study In Patients With Non-Diabetic Chronic Kidney Disease

Bayer Aktiengesellschaft to Report Q4, 2026 Results on Feb 24, 2027

BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings

Bayer Aktiengesellschaft to Report Q3, 2026 Results on Nov 03, 2026